Category: sirolimus

Six-month data from the Surmodics SWING BTK first-in-human trial presented at AMP Europe

Six-month data from the Surmodics SWING first-in-human (FIH) study of the company’s Sundance sirolimus drug-coated balloon (DCB) were shared at the 2022 Amputation Prevention Symposium (AMP; 9–11 October, Lugano, Switzerland). The SWING study is a prospective, multicentre, single-arm feasibility study to evaluate the safety and performance of the Sundance sirolimus DCB when used to treat […]

The post Six-month data from the Surmodics SWING BTK first-in-human trial presented at AMP Europe appeared first on Vascular News.

Preliminary MOTIV BTK outcomes positive for bioresorbable scaffold use in below-the-knee lesions

Thomas Rand (Klinik Florisdorf, Vienna, Austria) recently presented on the preliminary results to 12 months of the Motiv bioresorbable scaffold (Reva Medical) postmarket trial at the recent Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14 September, Barcelona, Spain). With the objective of evaluating safety and efficacy for the treatment of patients […]

The post Preliminary MOTIV BTK outcomes positive for bioresorbable scaffold use in below-the-knee lesions appeared first on Vascular News.

Japanese Selution SLR study completes enrolment

MedAlliance, with its Japanese partner MDK Medical, has completed enrolment in the clinical study of its novel sirolimus drug-eluting balloon (DEB), Selution SLR, for the treatment of peripheral arterial disease (PAD). This follows the acceptance of a Clinical Trial Notification (CTN) by Japan’s Pharmaceutical and Medical Device Agency (PMDA) in June 2020.  The study involves […]

The post Japanese Selution SLR study completes enrolment appeared first on Vascular News.